NCT02678455View on ClinicalTrials.gov

Safety and Immunogenicity of the Dengue Virus Vaccine TV005 (TetraVax-DV TV005) in Healthy Adults, Adolescents, and Children in Dhaka, Bangladesh

PHASE2CompletedINTERVENTIONAL
Enrollment

192

Participants

Timeline

Start Date

March 31, 2016

Primary Completion Date

August 10, 2017

Study Completion Date

February 5, 2020

Conditions
Dengue
Interventions
BIOLOGICAL

TV005 vaccine

Delivered by subcutaneous injection; contains 10\^3 PFU of rDEN1Δ30, 10\^4 PFU of rDEN2/4Δ30(ME), 10\^3 PFU of rDEN3Δ30/31, and 10\^3 PFU of rDEN4Δ30.

BIOLOGICAL

Placebo

Delivered by subcutaneous injection

Trial Locations (1)

Unknown

International Centre for Diarrhoeal Disease Research, Bangladesh, Mīrpur

All Listed Sponsors
collaborator

University of Vermont

OTHER

collaborator

Johns Hopkins Bloomberg School of Public Health

OTHER

lead

National Institute of Allergy and Infectious Diseases (NIAID)

NIH

NCT02678455 - Safety and Immunogenicity of the Dengue Virus Vaccine TV005 (TetraVax-DV TV005) in Healthy Adults, Adolescents, and Children in Dhaka, Bangladesh | Biotech Hunter | Biotech Hunter